Compare DexCom, Inc. (DXCM) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

PALL trades at $22.86, down 3.54% over 24 hours, amid a mixed technical backdrop with a bullish overall signal but neutral oscillators. The stock underwent a 1:5 forward split effective May 18, 2026, which adjusts share count without altering the ETF's net asset value. Recent financial news highlights palladium's underperformance relative to other precious metals, framing current price weakness as a potential buying opportunity due to supply risks and industrial demand.

The outlook for PALL hinges on palladium's commodity cycle, with bullish factors including constrained supply and sustained industrial use, though high volatility and macroeconomic sensitivity pose risks. Investor sentiment is cautiously optimistic, with analysts viewing the price drop as a chance for entry, but the ETF's performance remains tied to raw material price swings rather than corporate earnings.